We are strengthening our capabilities in ophthalmology as a part of our global specialty growth strategy, backed by strong research capabilities, advanced manufacturing, and strategic partnerships.
We continue to strengthen our biosimilar pipeline with ophthalmic products such as Ranibizumab and Aflibercept, developed at our Pune Biotech facility to address complex retinal and chorioretinal vascular disorders, and to improve global treatment access.
We have expanded global access to Ranibizumab biosimilars through strategic partnerships with Amman Pharma and Sandoz, strengthening our leadership in ophthalmic biosimilars worldwide.
Our Ranibizumab biosimilar has received approval from the European Medicines Agency (EMA).
With an evolving global presence, and a plethora of solutions, we at Lupin are committed to building a strong and holistic ophthalmology franchise.
Our ophthalmology portfolio is designed to address the full spectrum of eye care needs. The focus is to enable effective, long-term management across key areas.
These diseases are serious ophthalmic conditions affecting the retina and can lead to vision impairment or blindness. Key conditions include Neovascular (wet) Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV).
These disorders affect the cornea, conjunctiva, and tear film which can cause discomfort, inflammation, and visual disturbance. Common conditions include dry eye disease, blepharitis, allergic conjunctivitis, and meibomian gland dysfunction.
Glaucoma is a group of chronic eye diseases characterized by progressive optic nerve damage and visual field loss. It is the leading cause of irreversible blindness. Early detection and sustained treatment are essential to slow disease progression and preserve vision.
These diseases affect the eye and surrounding tissues. They may lead to visual impairment. Common conditions include conjunctivitis, keratitis, uveitis, and endophthalmitis, requiring timely diagnosis and appropriate management.
This category focuses on maintaining long term ocular health and visual function. Nutraceuticals support eye health and are indicated for individuals with dry AMD, to help reduce the risk of disease progression.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
At Lupin, we deliver comprehensive, high-quality solutions that cater to vision-related needs of patients across geographies.
Ranieyes injection contains Ranibizumab. It is used in the management of certain serious eye conditions, including those related to diabetes, ageing, and conditions affecting the retina. It works by inhibiting the growth of abnormal blood vessels in the eye, which may help in controlling disease progression and preventing vision loss.
Lupitros is an ocular therapy used in the management of increased pressure within the eye. By maintaining appropriate eye pressure, it may reduce the risk of vision-related complications.
This eye drop is made to provide lubrication and comfort to the eyes. It forms a protective layer over the eye surface and supports the eyes by reducing ocular irritation, redness, and discomfort.
Hydroeyes is a nano micellar formulation with enhanced solubility. It is designed to overcome key molecular challenges in the treatment of dry eye disease.
Through innovation, complex formulations, and global partnerships, our ophthalmic business continues to expand for better access and patient outcomes.
As the global demand for advanced eye care continues to rise, we at Lupin, remain focused on expanding our ophthalmology footprint through innovation, next-generation formulations, and global partnerships.
With continued investments in research-led segments like biosimilars, and specialty products, we strive to deliver high-quality ophthalmic solutions that improve vision outcomes and support patients worldwide.
